PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis ; volume:11 ; number:2 ; day:5 ; month:12 ; year:2013 ; pages:1-2 ; date:12.2013
Pediatric rheumatology ; 11, Heft 2 (5.12.2013), 1-2, 12.2013
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Anink, J.
Otten, MH
Van Suijlekom-Smit, LA
Van Rossum, MA
Dolman, KM
Hoppenreijs, EP
Ten Cate, R.
Vogl, T.
Foell, D.
Roth, J.
Holzinger, D.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1546-0096-11-S2-P157
- URN
-
urn:nbn:de:101:1-2019060907102216298412
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Anink, J.
- Otten, MH
- Van Suijlekom-Smit, LA
- Van Rossum, MA
- Dolman, KM
- Hoppenreijs, EP
- Ten Cate, R.
- Vogl, T.
- Foell, D.
- Roth, J.
- Holzinger, D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry